Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS2 | Q96GW9 | 10/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20595982 | 1.00 | MARS2 (0.47) | MARS2FPR2HSP90AA1HSP90AB1NOS3 | |
| SCHEMBL20596259 | 0.76 | MAOB (0.37) | ALDH1A1HPGDEGFR | |
| SCHEMBL20595817 | 0.75 | KDM4E (0.42) | PTGESALDH1A1 | |
| SCHEMBL20596021 | 0.74 | LMNA (0.41) | PTGES | |
| SCHEMBL20595846 | 0.65 | MARS2 (0.82) | MARS2FPR2NOS3NOS1NOS2 | |
| SCHEMBL20596195 | 0.65 | TAS1R3 (0.32) | ALDH1A1HPGDEGFR | |
| SCHEMBL30145097 | 0.65 | MARS2 (0.54) | MARS2NOS3NOS1NOS2 | |
| SCHEMBL20596054 | 0.65 | MARS2 (0.54) | MARS2NOS3NOS1NOS2 | |
| SCHEMBL20596125 | 0.64 | MARS2 (1.00) | MARS2FPR2NOS3NOS1NOS2 | |
| SCHEMBL23121351 | 0.64 | ATM (0.41) | MTNR1BALDH1A1HPGDEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | UNIVERSITY OF WASHINGTON (US) | 2023-02-21 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584744-B2 | Inhibitors of type 1 methionyl-tRNA synthetase and methods of using them | AARS1, EMG1, GARS1 | MARS2 12/4885FPR2 4177/4885HSP90AA1 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.